[HTML][HTML] Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: a long-term post-marketing study in Japan
M Adachi, M Kozawa, H Yoshisue, KL Milligan… - Respiratory …, 2018 - Elsevier
Abstract Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …
[PDF][PDF] Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan
M Adachi, M Kozawa, H Yoshisue… - Respiratory …, 2018 - nscpolteksby.ac.id
ABSTRACT Background: Omalizumab (anti-IgE monoclonal antibody) is an approved add-
on therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …
on therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …
[HTML][HTML] Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan
M Adachi, M Kozawa, H Yoshisue… - Respiratory …, 2018 - resmedjournal.com
Abstract Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …
Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan.
M Adachi, M Kozawa, H Yoshisue, M Nagasaki… - Respiratory …, 2018 - europepmc.org
Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on therapy for
Japanese patients with severe allergic asthma. As directed by the Ministry of Health, Labor …
Japanese patients with severe allergic asthma. As directed by the Ministry of Health, Labor …
Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan
M Adachi, M Kozawa, H Yoshisue… - Respiratory …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on therapy for
Japanese patients with severe allergic asthma. As directed by the Ministry of Health, Labor …
Japanese patients with severe allergic asthma. As directed by the Ministry of Health, Labor …
[引用][C] Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan
M Adachi, M Kozawa, H Yoshisue, KL Milligan… - Respiratory …, 2018 - cir.nii.ac.jp
Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term
post-marketing study in Japan | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
post-marketing study in Japan | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …